<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514603</url>
  </required_header>
  <id_info>
    <org_study_id>16018</org_study_id>
    <secondary_id>I4D-JE-JTJK</secondary_id>
    <nct_id>NCT02514603</nct_id>
  </id_info>
  <brief_title>A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers</brief_title>
  <official_title>A Phase 1 Study of LY2606368 in Japanese Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the tolerability of prexasertib in Japanese
      participants with advanced solid cancers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">April 10, 2017</completion_date>
  <primary_completion_date type="Actual">April 10, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Prexasertib Dose-Limiting Toxicities (DLT)</measure>
    <time_frame>Cycle 1 (14 day cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Prexasertib</measure>
    <time_frame>Pre-dose up to 7 Days Post Treatment in Cycle 1/2 (Approximately 7 Days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under Curve (AUC) of Prexasertib</measure>
    <time_frame>Pre-dose up to 7 Days Post Treatment in Cycle1/2 (Approximately 7 Days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Tumor Response</measure>
    <time_frame>Baseline to Study Completion (Approximately 24 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Neoplasm</condition>
  <arm_group>
    <arm_group_label>Prexasertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prexasertib intravenously (IV) on day 1 of a 14 day cycle. Treatment with prexasertib may continue until disease progression, unacceptable toxicity, or other discontinuation criteria are met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prexasertib</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Prexasertib</arm_group_label>
    <other_name>LY2606368</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must be appropriate candidate for experimental therapy, as determined by
             investigator, after available standard therapies have failed

          -  Participant must have diagnosis of cancer that is advanced or metastatic

          -  Participant must have discontinued previous treatments for cancer and recovered from
             the acute effects of that therapy

          -  If participant is of reproductive potential, must agree to use medically approved
             contraceptive precautions during the study and for three months following the last
             dose of study drug

          -  If the participant is a female of childbearing potential, must have had a negative
             serum or urine pregnancy test within 7 days of the first dose of study drug and must
             not be breast feeding

        Exclusion Criteria:

          -  Participant must not have symptomatic central nervous system malignancy or metastasis

          -  Participant must not have current hematologic malignancy

          -  Participant must not have an active symptomatic fungal, bacterial or viral infection,
             including human immunodeficiency virus (HIV) or Hepatitis A, B, or C

          -  Participant must not have a serious cardiac condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiba</city>
        <zip>277 8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>July 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2015</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasm metastasis</keyword>
  <keyword>Checkpoint Kinase 1</keyword>
  <keyword>CHK1</keyword>
  <keyword>CHK1 inhibitor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

